Clinical trial
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or…
NCT00030368 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030368 |
|---|---|
| Title | Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
| Official title | A Phase I Study of PS-341 in Combination With Paclitaxel in Metastatic Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | bortezomib, paclitaxel, laboratory biomarker analysis |
| Enrollment | 45 |
| Start date | Nov 1, 2001 |
| Primary completion | Feb 1, 2009 |
| First posted | Apr 9, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: